Novel oral cannabinoid formulations
AssigneeEsolate Pharmaceuticals Ltd
InventorsHardin Matthew Jackson, Devin Douglas Machin, Jinhee Oh, Venkat Reddy Goskonda, Andrew Jonathan Saich
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to novel pharmaceutical formulations, including solid oral dosage forms comprising the non-psychoactive cannabinoid cannabidiol (CBD). The disclosure further relates to methods of manufacture of the pharmaceutical formulations and the use of the formulations to treat diseases and conditions.
Claims24
A solid, oral pharmaceutical dosage form comprising cannabidiol, hydroxypropyl-β-cyclodextrin (HPBCD), poloxamer-188, and poloxamer-407, wherein the cannabidiol is present in an amount from 100-300 mg per unit dose.
A solid, oral pharmaceutical dosage form comprising per unit dose cannabidiol in an amount of from 100-300 mg, hydroxypropyl-β-cyclodextrin (HPβCD) in an amount of between 15% (w/w) and 35% (w/w), poloxamer-188 in an amount of between 20% (w/w) to 40% (w/w), and poloxamer-407 in an amount of between 5% (w/w) to 15% (w/w).
Dependencies are inferred from the claim text.